Clinical Trial Update: Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference. [NA]

View source ↗

Summary

This completed multicenter prospective study assessed the diagnostic accuracy of CAP measurements by FibroScan (M+ or XL+ probes) for non-alcoholic fatty liver …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Snippet

Sponsor: Echosens | Conditions: Non-alcoholic Fatty Liver Disease | NA | Status: COMPLETED